Governance for consistency across product, site and region CMC filings Governance for consistency across product, site and region CMC filings In the ever-evolving landscape of pharmaceutical and biopharmaceutical development, securing regulatory approval requires an intricate understanding of CMC (Chemistry, Manufacturing, and Controls) documentation. This regulatory explainer manual focuses on CMC documentation practices required for New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), and post-market supplements. Professionals in Regulatory Affairs (RA), Quality Assurance (QA), and technical operations should be keenly aware of how these processes interact with global regulatory bodies including the FDA, EMA, and MHRA….

Bridging legacy CMC dossiers to updated formats and expectations Bridging legacy CMC dossiers to updated formats and expectations Context of CMC Documentation in Regulatory Affairs Chemistry, Manufacturing, and Controls (CMC) documentation plays a pivotal role in the regulatory submission process for pharmaceutical and biotechnology products. This encompasses both New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Biologics License Applications (BLAs). The evolving landscape of regulatory expectations necessitates a systematic approach to updating legacy CMC dossiers to align with new formats and requirements, particularly in the context of electronic submissions such as the eCTD (electronic Common Technical Document). Legal…

CMC documentation nuances for generic ANDA versus innovative NDA CMC Documentation Nuances for Generic ANDA versus Innovative NDA Regulatory Affairs Context In the complex world of pharmaceutical development, Regulatory Affairs (RA) professionals must navigate a myriad of guidelines, regulations, and expectations surrounding Chemistry, Manufacturing, and Controls (CMC) documentation. Understanding the nuances between a New Drug Application (NDA) and an Abbreviated New Drug Application (ANDA) is critical, especially when considering the specificity required in documentation, review processes, and agency expectations. This article aims to serve as a comprehensive guide for RA professionals in the context of both NDA and ANDA submissions,…

Handling post approval CMC documentation updates efficiently Handling Post Approval CMC Documentation Updates Efficiently Context In the pharmaceutical and biotechnology sectors, the lifecycle management of Chemistry, Manufacturing, and Controls (CMC) documentation is crucial for maintaining compliance with regulatory expectations. This article outlines the intricacies of post-approval CMC documentation updates, relevant regulations, and guidelines affecting New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Biologics License Applications (BLAs) in the US, UK, and EU markets. Legal/Regulatory Basis The legal framework for CMC documentation is anchored in various regulations and guidelines. In the United States, the Food and Drug Administration (FDA)…

Audit and inspection readiness of CMC files across the lifecycle Audit and Inspection Readiness of CMC Files Across the Lifecycle In the highly regulated environment of pharmaceutical and biotech industries, ensuring the integrity and compliance of Chemistry, Manufacturing, and Controls (CMC) documentation is paramount. This article serves as a comprehensive regulatory explainer manual aimed at Kharma and regulatory professionals focused on the CMC documentation for New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), and post-market supplements. It details the regulatory framework, documentation requirements, review processes, potential deficiencies, and best practices for maintaining inspection readiness throughout…